Rheumatoid arthritis patients in rich countries are three times more likely to receive biologic treatment than those in poor countries

There is significant disparity between "richer" and "poorer" countries in terms of access to biological treatments for rheumatoid arthritis (RA), according to results from a multinational study across four continents. Furthermore, findings from a separate study show that RA patients report the severity of their disease in the same way, irrespective of the country where they live.

Read the whole article on Science Daily

More from Science Daily